Moderna, Inc. (LON:0A45)

Market Cap	8.11B
Revenue (ttm)	2.25B
Net Income (ttm)	-2.12B
Shares Out	n/a
EPS (ttm)	-5.49
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	45,979
Average Volume	61,982
Open	34.25
Previous Close	34.06
Day's Range	33.37 - 34.30
52-Week Range	23.16 - 125.48
Beta	1.85
RSI	36.91
Earnings Date	Jul 31, 2025

About Accolade

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2010
• Employees: 5,800
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A45

Financial Performance

In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.